EWA
ADAP

EverSource Wealth Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

EverSource Wealth Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100
Closed -$13 – 4272
2025
Q3 		$13 Buy
+100
New +$14 ﹤0.01% 4293

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

EverSource Wealth Advisors's ADAP Position: Q4 2025 in Review

EverSource Wealth Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 100 shares — an estimated $13 sold.

EverSource Wealth Advisors first reported a position in ADAP in Q3 2025 and held it in 1 quarter. The position peaked at $13 in Q3 2025. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • EverSource Wealth Advisors reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • EverSource Wealth Advisors sold 100 Adaptimmune Therapeutics shares in Q4 2025, an estimated $13.
  • EverSource Wealth Advisors first reported a position in Adaptimmune Therapeutics in Q3 2025 and held it in 1 quarter.
  • EverSource Wealth Advisors's Adaptimmune Therapeutics position peaked at $13 in Q3 2025.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on EverSource Wealth Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.